Forbes April 17, 2024
A study just published in JAMA could unveil a new direction in the landscape of weight loss interventions. Endoscopic sleeve gastroplasty, or ESG, has emerged as a more cost-effective option for losing significant amounts of weight compared to using semaglutide, the active ingredient in popular weight loss drugs such as Ozempic and Wegovy. ESG also proved to be more effective at helping patients lose more weight than the medications over a five-year time horizon.
ESG stomach tightening is a minimally invasive, non-surgical procedure for weight loss that reduces the size and capacity of the stomach by 70%, creating a sleeve-like shape. The endoscopic procedure takes less than 60 minutes to perform and patients lose an average of 18% of their...
Today's Sponsors
Today's Sponsor